GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (FRA:OJU1) » Definitions » Beneish M-Score

Oramed Pharmaceuticals (FRA:OJU1) Beneish M-Score : -1.93 (As of May. 20, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Oramed Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.93 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Oramed Pharmaceuticals's Beneish M-Score or its related term are showing as below:

FRA:OJU1' s Beneish M-Score Range Over the Past 10 Years
Min: -3.16   Med: -2.24   Max: 7.05
Current: -1.93

During the past 13 years, the highest Beneish M-Score of Oramed Pharmaceuticals was 7.05. The lowest was -3.16. And the median was -2.24.


Oramed Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Oramed Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Beneish M-Score Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.00 -1.14 -1.77 -3.03 1.34

Oramed Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.92 -2.64 0.30 1.34 -1.93

Competitive Comparison of Oramed Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Oramed Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Beneish M-Score falls into.



Oramed Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Oramed Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 7.2188+0.892 * 0.24+0.115 * 0.3277
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 3.0687+4.679 * 0.081447-0.327 * 4.7939
=-1.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was €0.00 Mil.
Revenue was 0 + 0 + 0 + 0.622 = €0.62 Mil.
Gross Profit was 0 + 0 + 0 + 0.622 = €0.62 Mil.
Total Current Assets was €162.93 Mil.
Total Assets was €187.36 Mil.
Property, Plant and Equipment(Net PPE) was €1.31 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.20 Mil.
Selling, General, & Admin. Expense(SGA) was €7.83 Mil.
Total Current Liabilities was €30.87 Mil.
Long-Term Debt & Capital Lease Obligation was €0.25 Mil.
Net Income was 1.413 + 12.229 + -3.019 + -1.102 = €9.52 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0.00 Mil.
Cash Flow from Operations was -1.358 + -1.3 + -0.65 + -2.431 = €-5.74 Mil.
Total Receivables was €0.00 Mil.
Revenue was 0.622 + 0.643 + 0.689 + 0.638 = €2.59 Mil.
Gross Profit was 0.622 + 0.643 + 0.689 + 0.638 = €2.59 Mil.
Total Current Assets was €144.92 Mil.
Total Assets was €149.24 Mil.
Property, Plant and Equipment(Net PPE) was €1.77 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.08 Mil.
Selling, General, & Admin. Expense(SGA) was €10.63 Mil.
Total Current Liabilities was €4.64 Mil.
Long-Term Debt & Capital Lease Obligation was €0.53 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.622) / (0 / 2.592)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.592 / 2.592) / (0.622 / 0.622)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (162.927 + 1.313) / 187.36) / (1 - (144.917 + 1.767) / 149.235)
=0.123399 / 0.017094
=7.2188

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.622 / 2.592
=0.24

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.08 / (0.08 + 1.767)) / (0.2 / (0.2 + 1.313))
=0.043313 / 0.132188
=0.3277

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(7.83 / 0.622) / (10.633 / 2.592)
=12.588424 / 4.102238
=3.0687

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.25 + 30.872) / 187.36) / ((0.527 + 4.644) / 149.235)
=0.166108 / 0.03465
=4.7939

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(9.521 - 0 - -5.739) / 187.36
=0.081447

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Oramed Pharmaceuticals has a M-score of -1.94 suggests that the company is unlikely to be a manipulator.


Oramed Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals (FRA:OJU1) Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Oramed Pharmaceuticals (FRA:OJU1) Headlines

No Headlines